Protease inhibitors: Synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O- methylsulfonylisourea moieties at P1

Journal of Medicinal Chemistry

Volumn 43, Issue 9, 2000, Pages 1793-1806

  Supuran, Claudiu T ^a   Scozzafava, Andrea ^a   Briganti, Fabrizio ^a   Clare, Brian W ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; BENZAMIDINE DERIVATIVE; GUANIDINE DERIVATIVE; INOGATRAN; SERINE PROTEINASE; SULFONYLUREA DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; TRYPSIN;

ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THROMBOSIS;

COMPUTER SIMULATION; DRUG DESIGN; GUANIDINE; HUMANS; REGRESSION ANALYSIS; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; TRYPSIN INHIBITORS; UREA;

EID: 0034108113     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9903693     Document Type: Article

References (73)

1. Shafer, J. A. Cardiovascular chemotherapy: anticoagulants. Curr. Opin. Chem. Biol. 1998, 2, 458-465.
2. (a) Stürzebecher, J.; Meier, J. Synthetic low-molecular weight thrombin inhibitors: The ideal antithrombotic drug? J. Enzyme Inhib. 1995, 9, 1-2.
3. (b) Stürzebecher, J.; Prasa, D.; Hauptmann, J., Vieweg, H.; Wikstrom, P. Synthesis and structure-activity relationships of potent thrombin inhibitors: Piperazides of 3-amidinophenylalanine. J. Med. Chem. 1997, 40, 3091-3099.
4. (a) Pavone, V.; De Simone, G.; Nastri, F.; Galdiero, S.; Staiano, N.; Lombardi, A.; Pedone, C. Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis. Biol. Chem. 1998, 379, 987-1006.
5. (b) De Simone, G.; Lombardi, A.; Galdiero, S.; Della Morte, R.; Staiano, N.; Pedone, C.; Bolognesi, M.; Pavone, V. Hirunorms are true hirudin mimetics: the crystal structure of human α-thrombin: hirunorm V complex. Protein Sci. 1998, 7, 243-253.
6. (a) Stubbs, M. T.; Bode, W. A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 1993, 69, 1-58.
7. (b) Engh, R. A.; Brandstetter, H.; Sucher, G.; Eichinger, A.; Baumann, U.; Bode, W.; Huber, R.; Poll, T.; Rudolph, R.; von der Saal, W. Enzyme flexibility and "weak" interactions characterize thrombin-ligand interactions: implications for drug design. Structure 1996, 4, 1353-1362.
8. (a) Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: Application to drug design. Chem. Rev. 1997, 97, 1359-1472.
9. (b) Salemme, F. R.; Spurlino, J.; Bone, R. Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. Structure 1997, 5, 319-324.
10. Eriksson, U. G.; Renberg, L.; Bredberg, U.; Teger-Nilsson, A. C.; Regardh, C. G. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm. Drug Dispos. 1998, 19, 55-64.
11. (a) Bajusz, S.; Barbas, E.; Tolnay, P.; Szell, E.; Bagdy, D. Inhibition of thrombin and trypsin by tripeptide aldehydes. Int. J. Pept. Protein Res. 1978, 12, 217-221.
12. (b) Bajusz, S.; Szell, E.; Bagdy, D.; Barbas, E.; Horvath, G.; Dioszegi, M.; Fittler, Z.; Szabo, G.; Juhasz, A.; Tomori, E.; Szilagyi, G. Highly active and selective anticoagulants. D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative D-Me-Phe-Pro-Arg-H. J. Med. Chem. 1990, 33, 1729-1735.
13. Krishnan, R.; Zhang, E.; Hakansson, K.; Arni, R. K.; Tulinsky, A.; Lim-Wilby, M. S.; Levy, O. E., Semple, J. E., Brunck, T. K. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry 1998, 37, 12094-13103.
14. Claeson, G.; Philipp, M.; Agner, E.; Scully, M. F.; Metternich, R.; Kakkar, V. V.; DeSoyza, T.; Niu, L. H. Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position. Biochem. J. 1993, 290, 309-312.
15. (a) Stürzebecher, J.; Vieweg, H.; Wikstrom, P.; Turk, D.; Bode, W., Interaction of thrombin with benzamidine-based inhibitors. Biol. Chem. Hoppe-Seyler 1992, 373, 491-496.
16. (b) Stürzebecher, J.; Prasa, D.; Bretschneider, E.; Bode, W.; Bauer, M.; Brandstetter, H.; Wikstrom, P.; Vieweg, H. New developments in the field of benzamidine-derived thrombin inhibitors. In DIC -Pathogenesis, Diagnosis, and Therapy of Disseminated Intravascular Fibrin Formation; Muller-Berghaus, G., Madlener, K., Blomback, M., ten Cate, J. W., Eds.; Excerpta Medica: Amsterdam, London, New York, Tokyo, 1993; pp 183-190.
17. (a) Adang, A. E.; Lucas, H.; de Man, A. P.; Engh, R. A.; Grootenhuis, P. D. Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety. Bioorg. Med. Chem. Lett. 1998, 8, 3603-3608.
18. (b) Lumma, W. C.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas. B. J.; Vacca, J. P. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J. Med. Chem. 1998, 41, 1011-1013.
19. (c) Reers, M.; Koschinsky, R.; Dickneite, G.; Hoffmann, D.; Czech, J.; Stuber, W. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. J. Enzyme Inhib. 1995, 9, 61-72.
20. 1. J. Med. Chem. 1996, 39, 4527-4530.
21. (b) Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ha-Uong, T.; Minami, N. K.; Owens, T. D.; Tamura, S. Y.; Goldman, E. A.; Siev, D. V.; Ardecky, R. J.; Carpenter, S. H.; Ge, Y.; Richard, B. M.; Nolan, T. G.; Hakanson, K.; Tulinsky, A.; Nutt, R. F.; Ripka, W. C. Design, synthesis, and evolution of a novel selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties. J. Med. Chem. 1996, 39, 4531-4536.
22. Sixma, J. J.; de Groot, P. G. The ideal antithrombotic drug. Thromb. Res. 1992, 68, 507-512.
23. Okamoto, S.; Kinjo, K.; Hijikata, A.; Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tonomura, S. Thrombin inhibitors. 1. Ester derivatives of Nα-(arylsulfonyl)-L-arginine. J. Med. Chem. 1980, 23, 827-830.
24. (a) Stürzebecher, J.; Markwardt, F.; Voigt, B.; Wagner, G.; Walsmann, P. Cyclic amides of Nα-arylsulfonylamino acylated 4-amidinophenylalanine - tight binding of thrombin. Thromb. Res. 1983, 29, 635-642.
25. (b) Stürzebecher, J.; Markwardt, F.; Voigt, B.; Wagner, G. Inhibition of bovine and human thrombins by derivatives of benzamidines. Thromb. Res. 1984, 36, 457-467.
26. Groutas, W. C.; Kuang, R.; Venkataraman, R.; Epp, J. B.; Ruan, S.; Prakash, O. Structure-based design of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scaffold. Biochemistry 1997, 36, 4739-4750.
27. (a) Supuran, C. T.; Briganti, F.; Scozzafava, A. Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J. Enzyme Inhib. 1997, 12, 175-190.
28. (b) Briganti, F.; Pierattelli, R.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors Part 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes. Eur. J. Med. Chem. 1996, 31, 1001-1010.
29. (a) Supuran, C. T.; Ilies, M. A.; Scozzafava, A. Carbonic anhydrase inhibitors Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur. J. Med. Chem. 1998, 33, 739-752.
30. (b) Mincione, F.; Menabuoni, L.; Briganti, F.; Mincione, G.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Inhibition of isozymes I, II and IV with N-hydroxysulfonamides - A novel class of intraocular pressure lowering agents. J. Enyme Inhib. 1998, 13, 267-284.
31. Winnek, P. S.; Anderson, G. W.; Marson, H. W.; Faith, E.; Roblin, R. O., Jr. Studies in chemotherapy. V. Sulfanilylcyanamide and related compounds. J. Am. Chem. Soc. 1942, 64, 1682-1685.
32. Supuran, C. T.; Scozzafava, A.; Briganti, F. Carbonic anhydrase inhibitors: N-Cyanosulfonamides, a new class of high affinity isozyme II and IV inhibitors. J. Enyme Inhib. 1999, 14, 289-306.
33. Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Arylsulfonylureido and arylureido-substituted aromatic and heterocyclic sulfonamides: towards selective inhibitors of carbonic anhydrase isozyme I. J. Enzyme Inhib. 1999, 15, 343-363.
34. (a) Anderson, G. W.; Zimmerman, J. E.; Callahan, F. M. N-Hydroxysuccinimide esters in peptide synthesis. J. Am. Chem. Soc. 1963, 85, 3039.
35. (b) Sheehan, J. C.; Ledis, S. L. Total synthesis of a monocyclic peptide lactone antibiotic, etamycin. J. Am. Chem. Soc. 1973, 95, 875-879.
36. (c) Zlatoidsky, P.; Maliar, T. Synthesis of 4-(4-guanidinobenzoyloxy)benzamides and 1-(4-guanidinobenzoyloxy)benzoyloxy acetamides as trypsin inhibitors. Eur. J. Med. Chem. 1996, 31, 895-900.
37. Lottenberg, R.; Christensen, U.; Jackson, C. M.; Coleman, P. L. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol. 1981, 80, 341-361.
38. Clare, B. W.; Scozzafava, A.; Briganti, F.; Iorga, B.; Supuran, C. T. Protease inhibitors: Synthesis and QSAR study of nonbasic thrombin inhibitors incorporating sulfonylguanidine moieties as S1 anchoring groups. J. Enzyme Inhib., in press.
39. Hyperchem v. 5.1; available from Hypercube, Inc., 1115 NW 4th St., Gainesville, FL 32601-4256.
40. Stewart, J. J. P. MOPAC: A general molecular orbital package, version 6.0. QCPE Bull. 1990, 10, 86-87.
41. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A new general purpose quantum mechanical model. J. Am. Chem. Soc. 1985 107, 3902-3909.
42. Stewart, J. J. P. MOPAC 93.00; Fujitsu Ltd.: Tokyo, Japan, 1993. Also Stewart, J. J. P. MOPAC93 Release 2. QCPE Bull. 1995, 15, 13-14 (copyright Fujitsu 1993, all rights reserved).
43. Stewart, J. J. P. MOPAC 93.00; Fujitsu Ltd.: Tokyo, Japan, 1993. Also Stewart, J. J. P. MOPAC93 Release 2. QCPE Bull. 1995, 15, 13-14 (copyright Fujitsu 1993, all rights reserved).
44. Klamt, A.; Sshüürman, G. COSMO: A new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J. Chem. Soc., Perkin Trans. 2 1993, 799-805.
45. Clare, B. W. The Frontier Orbital Phase Angles: Novel QSAR Descriptors for Benzene Derivatives, Applied to Phenylalkylamine Hallucinogens. J. Med. Chem. 1998, 41, 3845-386.
46. Fukui, K.; Yonezawa, T.; Nagata, C. Theory of Substitution in Conjugated Molecules. Bull. Chem. Soc. Jpn. 1954, 27, 423-427.
47. Kikuchi, O. Systematic QSAR Procedures with Quantum Chemical Descriptors Quant. Struct.-Act. Relat. 1987, 6, 179-184.
48. ClogP for Windows, v. 1.0.0; available from BioByte Corp., 201 West 4th St., Suite 204, Claremont, CA 91711.
49. BMDP Dynamic, release 7; available from BMDP Statistical Software, Inc., 1440 Sepulveda Blvd., Suite 316, Los Angeles, CA 90025.
50. Furnival, G. M.; Wilson R. W. Regression by leaps and bounds. Technometrics 1974, 16, 499-511.
51. Chatterjee, S.; Price, B. Regression Analysis by Example, 1st ed.; Wiley: New York, 1977; pp 199-200.
52. Topliss, J. G.; Costello, R. J. Chance correlations in structure activity studies using multiple regression analysis. J. Med. Chem. 1972, 15, 1066-1068.
53. Topliss, J. G.; Edwards, R. J. Chance Factors in Studies of Quantitative Structure-Activity Relationships. J. Med. Chem. 1979, 22, 1238-1244.
54. Efroymson, M. A. Multiple Regression Analysis. In Mathematical Methods for Digital Computers; Ralston, A., Wilf, H. S., Eds.; Wiley: New York, 1962; p 191.
55. Clare, B. W. Alternating conditional expectations in QSAR. In Methods and Principles in Medicinal Chemistry; Mannhold, R., Krogsgaard-Larsen, P., Timmerman, H., Eds.; VCH: Weinheim, 1994. Advanced Computer-Assisted Techniques in Drug Discovery; van de Waterbeemd, H., Ed.; pp 284-289.
56. Clare, B. W. Alternating conditional expectations in QSAR. In Methods and Principles in Medicinal Chemistry; Mannhold, R., Krogsgaard-Larsen, P., Timmerman, H., Eds.; VCH: Weinheim, 1994. Advanced Computer-Assisted Techniques in Drug Discovery; van de Waterbeemd, H., Ed.; pp 284-289.
57. Clare, B. W. Structure-activity correlations for psychotomimetics. 2. Phenylalkylamines: a treatment of nonlinearity using the alternating conditional expectation technique Chemom. Intell. Lab. Syst. 1993, 18, 71-93.
58. Banner, D. W.; Hadvary, P. Crystallographic analysis at 3.0 Å resolution of the binding to human thrombin of four active site-directed inhibitors. J. Biol. Chem. 1991, 266, 20085-20093.
59. Gaussian 94, revision A.1; M. J. Frisch, G. W. Trucks, H. B. Schlegel, P. M. W. Gill, B. G. Johnson, M. A. Robb, J. R. Cheeseman, T. A. Keith, G. A. Petersson, J. A. Montgomery, K. Raghavachari, M. A. Al-Laham, V. G. Zakrzewski, J. V. Ortiz, J. B. Foresman, C. Y. Peng, P. Y. Ayala, M. W. Wong, J. L. Andres, E. S. Replogle, R. Gomperts, R. L. Martin, D. J. Fox, J. S. Binkley, D. J. Defrees, J. Baker, J. P. Stewart, M. Head-Gordon, C. Gonzalez, J. A. Pople; Gaussian, Inc.: Pittsburgh, PA, 1995.
60. Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B 1988, 37, 785-789.
61. Parr, R. G.; Yang, W. Density-functional theory of atoms and molecules; Oxford University Press: Oxford, 1989.
62. Foresman, J. B.; Keith, T. A.; Wiberg, K. B.; Snoonian, J.; Frisch, M. J. Solvation Effects 5. Influence of Cavity Shape, Truncation of Electrostatics, and Electron Correlation on ab Initio Reaction Field Calculations. J. Phys. Chem. 1996, 100, 16098-16104.
63. a Prediction Module, pKalc 3.1; available from CompuDrug Chemistry Ltd., H-1395 Budapest, 62 P.O.B. 405, Hungary.
64. Balasubramanian, N.; Laurent, D. R. S.; Federici, M. E.; Meanwell, N. A.; Wright, J. J.; Schumacher, W. A.; Seiler, S. M. Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BYM 44621 and analogues. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series. J. Med. Chem. 1993, 36, 300-303.
65. Bode, W.; Turk, D.; Stürzebecher, J. Geometry of binding of benzamidine and arginine-based inhibitors NAPAP and MQPA to human α-thrombin: X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur. J. Biochem. 1990, 193, 175-182.
66. Czapinska, H.; Otlewski, J. Structural and energetic determinants of the S1-site specificity in serine proteases. Eur. J. Biochem. 1999, 260, 571-595.
67. Stone, S. R.; Le Bonniec, B. F. Thrombin. In Handbook of Proteolytic Enzymes, CD-ROM, Barrett, A. J., Rawlings, N. D., Woessner, J. F., Eds.; Academic Press: London, 1998; Chapter 55.
68. Bode, W.; Turk, D.; Karshikov, A. The refined 1.9-AX-ray crystal structure of D-Phe-Pro-Arg chloromethyl ketone-inhibited human α-thrombin; structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationship. Protein Sci. 1992, 1, 426-471.
69. Rezaie, A. R.; Esmon, C. T. Molecular basis of residue 192 participation in determination of coagulation protease specificity. Eur. J. Biochem. 1996, 242, 477-484.
70. Clare, B. W. The frontier orbital phase angles: A theoretical interpretation. J. Mol. Struct. (THEOCHEM). in press.
71. Gomez-Jeria, J. S. Calculation of the nucleophilic superdelocalizability by the CNDO method. J. Pharm. Sci. 1982, 71, 1423-1424.
72. Bell, P. H.; Roblin, R. O. Studies in chemotherapy. VII. A theory of the relation of structure to activity of sulfanilamide type compounds. J. Am. Chem. Soc. 1942, 64, 2905-2917.
73. Hemker, H. C.; Willems, G. M.; Beguin, S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay process. Thromb. Haemostasis 1986, 56, 9-17.